← All trials
NCT07165067
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2025
- Primary completion
- Dec 27, 2027
- Completion date
- Jan 30, 2028
- First posted
- Sep 10, 2025
- Last posted
- Sep 10, 2025
- Enrollment
- 36
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- OBI Pharma, IncLead sponsor
- Avance Clinical Pty Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.